What Is the PCAC, and Why Does It Matter for Peptides?

The PCAC (Pharmacy Compounding Advisory Committee) is a panel of outside experts. The FDA asks it for advice before deciding which ingredients compounding pharmacies may use. A compounding pharmacy is one that mixes custom medications from raw ingredients instead of handing out a factory-made drug.

The committee’s votes are recommendations, not rulings. In July 2026 the PCAC reportedly voted in favor of six popular peptides, but their legal status didn’t change that day. The FDA still has to make its own decision and then write a formal rule.

If you’ve seen a headline saying “BPC-157 is coming back” or “FDA committee backs peptides,” this page explains what actually happened and what comes next. Peptides are short chains of amino acids, the building blocks of proteins. If you’re new to them, start with what peptides are.

What is the PCAC?

FDA describes the Pharmacy Compounding Advisory Committee as the group that advises it on scientific, technical, and medical questions about compounding. Compounding means a pharmacist preparing a custom version of a medication.

The committee covers two kinds of compounders, and each is named after a section of federal drug law:

• 503A pharmacies are state-licensed pharmacies that compound a medication for one patient’s prescription. This is the kind most people picture.
• 503B outsourcing facilities are facilities that make sterile drugs, choose to register with FDA, and are inspected by FDA on a risk-based schedule, under 21 U.S.C. 353b. Unlike 503A pharmacies, they don’t need a prescription for each individual patient.

Key facts at a glance:

• Created under: the Federal Food, Drug, and Cosmetic Act, the main federal drug law.
• Voting members: a core of 12, per FDA.
• Role: advisory only.
• Who decides: FDA makes the final call.

Who sits on it?

According to FDA, the committee has a core of 12 voting members, including a chair. Members include:

• Representatives drawn from the National Association of Boards of Pharmacy, the group that coordinates state pharmacy regulators.
• Representatives from the US Pharmacopeia, the nonprofit that sets quality standards for drug ingredients.
• Compounding pharmacists and physicians.
• Patient or consumer representatives.

FDA also notes that the committee may include non-voting members who represent industry interests.

Members rotate, so we don’t list names here. The current lineup is on FDA’s PCAC roster page.

Why does a committee get a say? The law behind it

Under federal law (21 U.S.C. 353a), a 503A pharmacy may compound only from ingredients that pass one of three tests:

1. The ingredient meets a US Pharmacopeia quality standard, called a “monograph.”
2. The ingredient is already part of an FDA-approved drug.
3. The ingredient appears on FDA’s “503A bulks list,” the official list of raw ingredients approved for compounding.

Peptides like BPC-157 don’t pass either of the first two tests. That leaves the bulks list as the only legal route for them.

The same law requires FDA to “convene and consult” an advisory committee before it issues the regulations that create that list. The only exception is when public health requires faster action. The PCAC is that committee, and that’s why its votes get so much attention.

How a peptide gets from “nominated” to “allowed”

FDA’s 503A bulk substances page and its briefing introduction lay out the path:

1. Nomination. Someone formally asks FDA to consider the substance.
2. FDA review. FDA staff judge the substance on four things: how well its chemical makeup is understood, its safety, the evidence that it works, and how long it has been used in compounding.
3. PCAC meeting and vote. The committee hears FDA’s review and public comment, then votes in a public meeting.
4. FDA decision. FDA decides whether to agree with the committee. It isn’t required to.
5. Proposed rule. If FDA moves ahead, it publishes a proposed rule in the Federal Register, the government’s official daily journal of new rules.
6. Public comment. Anyone can weigh in during a set comment period.
7. Final rule. Only at this point may 503A pharmacies legally compound the substance from raw ingredients.

While nominations wait, FDA sorts them into interim groups:

• Category 1: substances with enough supporting information to be considered for the list. FDA has said it doesn’t intend to take action against compounding with them while it evaluates, as long as certain conditions are met.
• Category 2: substances FDA has flagged as possibly posing significant safety risks.
• Category 3: substances nominated without enough supporting information.

FDA’s page also notes that substances nominated on or after January 7, 2025 won’t be placed into these interim categories.

You may also hear that some peptides were “withdrawn from Category 2.” That means the nomination was pulled, so FDA’s safety-risk listing no longer applies to that substance. It does not put the substance in Category 1, and it does not put it on the bulks list. FDA’s Category 2 page shows the July peptides in that withdrawn table.

Could the vote matter before a final rule? The law firm McDermott expects FDA may use some informal enforcement discretion in the meantime. In practice, that would mean going easier on pharmacies while it writes the rule. McDermott advises clients in this space. Its view is a prediction, not FDA policy, and we found no FDA statement promising that kind of leniency.

What the July 2026 meeting actually decided, and what it didn’t

The PCAC met over two days, according to FDA’s meeting page and the Federal Register notice (Docket FDA-2025-N-6895):

• July 23: BPC-157, KPV, TB-500, MOTS-c
• July 24: Emideltide (DSIP), Semax, Epitalon

FDA’s own reviewers recommended against adding these peptides to the bulks list. FDA’s BPC-157 briefing document states this directly, citing gaps in data on the peptide’s identity and purity, a possible risk of immune reactions, and limited safety data. Mintz reports that FDA recommended against all seven, citing a lack of clinical data or poor characterization (how well the substance’s makeup is pinned down), among other reasons.

FDA had not posted official minutes or vote results when we checked. The outcomes below come from the law firm McDermott, and AJMC reported the same outcomes.

Reported PCAC vote, July 23–24, 2026 (tallies as reported by McDermott, shown as yes–no–abstain)

This was a real vote, not hype. A majority of an expert panel sided with listing six of seven peptides, against the advice of FDA’s own staff. The margins were also narrow: four of the six yes votes passed by two votes, the other two by three, and DSIP failed by one. Both facts matter.

The vote wasn’t a verdict on whether the peptides work, either. For BPC-157, FDA’s briefing found five small human studies in the published literature. The largest enrolled 53 people with ulcerative colitis (a chronic inflammatory bowel disease); the others were smaller studies of knee pain, a bladder condition, healthy volunteers, and just 2 people given it by IV. FDA noted that no serious side effects appear to have been reported. It also called the studies short, small, and light on safety detail. So there is some human data, but it’s early-stage and nowhere near proof that BPC-157 works for anything. Our BPC-157 entry covers the evidence in detail.

What a “yes” vote does — and doesn’t — change for you

What it doesn’t do: A yes vote doesn’t make any of these peptides FDA-approved. It doesn’t make them eligible for compounding yet, either. As of October 2026, none of the peptides voted on in July is on FDA’s 503A bulks list, and FDA has not issued a proposed rule on them.

The vote also doesn’t change what “research use only” websites sell or what they guarantee. A vial bought from one of those sites today is no different than it was before July.

What it does do: It’s the furthest these peptides have gotten toward a legal, prescription-based compounding route. Mintz reports that committee members who voted yes argued that listing would move patients from the gray market to supervised sources, and could make further study easier. That’s a fair point about access, and the gray market is real. The Alliance for Pharmacy Compounding, the trade group for compounding pharmacies (which would gain business from listing), made the same case to the committee. It argued that a total ban in the regulated channel could raise overall risk by pushing patients toward the least transparent sellers.

But it’s an argument about access, not evidence that the peptides work or are safe. REVIEW FDA’s reviewers still recommended against listing. Mintz also notes that listing could reduce drug companies’ incentive to run full clinical trials. Supporters on the committee had an answer to that, according to McDermott: these simple peptides are hard to patent, so drug companies may have little reason to fund those trials anyway. That’s a fair point too, but it doesn’t fill the evidence gap. It only explains why the gap may stay open.

As noted above, some lawyers expect FDA may go easier on enforcement while it writes a rule. Until FDA says so itself, treat that as an educated guess.

Where these peptides are actually sold right now, and what each channel guarantees

Here is the honest picture as of October 2026:

• “Research use only” websites are a major source today. They sell straight to consumers with no prescription, and even the compounding industry’s trade group describes them as an established illicit market that uses the “research use only” label to sidestep FDA while selling to people. That channel comes with no FDA manufacturing oversight, no guarantee that the vial holds what the label says, no medical supervision, and no legal protection. The PCAC vote changes none of that.
• Telehealth and medspa clinics sometimes offer these peptides. If a real consultation happens, you get a licensed prescriber. A prescription doesn’t fix the ingredient’s legal status, though, and what you receive depends on the pharmacy behind the clinic.
• 503A compounding pharmacies offer real protections: state licensure, a pharmacist who is accountable for what’s in the vial, and a prescriber in the loop. Compounded drugs still aren’t FDA-approved, and FDA doesn’t review them before they’re dispensed. These protections also only matter once an ingredient is legal to compound, and the July peptides aren’t yet.

In short, a favorable vote is a step toward a regulated, prescription-based route. That route doesn’t exist yet, and the vote says nothing about what’s in a research-use vial today.

What could change next

The next thing to watch for is an FDA proposed rule on the July peptides in the Federal Register. That’s the step that would actually start changing their legal status. It may not be quick: McDermott says rulemaking could happen in 2027 or stretch over several years, and the law firm Buchanan Ingersoll & Rooney notes that FDA’s last comparable bulks rule took more than two years to go from proposed to final. Both firms advise clients in this area.

FDA’s page for 2027 meetings shows only an early announcement, with no substances listed that we could read. McDermott reports that GHK-Cu, Dihexa, LL-37, PEG-MGF, and Melanotan II are slated for a meeting before February 2027. That’s McDermott’s report, not something FDA has posted.

Status changes quickly, so we keep it in one place. Our Regulatory Tracker shows where each peptide stands, and we check it every week. For one compound in depth, see BPC-157’s legal status.

FAQs about PCAC